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Abstract
Constitutive expression of active Akt (Akttg) drives hyperplasia and hypertrophy of pancre-
atic β-cells, concomitantly with increased insulin secretion and improved glucose tolerance,
and at a later stage the development of insulinoma. To determine which functions of Akt are
mediated by ribosomal protein S6 (rpS6), an Akt effector, we generated mice that express
constitutive Akt in β-cells in the background of unphosphorylatable ribosomal protein S6
(rpS6P-/-). rpS6 phosphorylation deficiency failed to block Akttg-induced hypertrophy and
aneuploidy in β-cells, as well as the improved glucose homeostasis, indicating that Akt car-
ries out these functions independently of rpS6 phosphorylation. In contrast, rpS6 phosphor-
ylation deficiency efficiently restrained the reduction in nuclear localization of the cell cycle
inhibitor p27, as well as the development of Akttg-driven hyperplasia and tumor formation in
β-cells. In vitro experiments with Akttg and rpS6P-/-;Akttg fibroblasts demonstrated that rpS6
phosphorylation deficiency leads to reduced translation fidelity, which might underlie its
anti-tumorigenic effect in the pancreas. However, the role of translation infidelity in tumor
suppression cannot simply be inferred from this heterologous experimental model, as rpS6
phosphorylation deficiency unexpectedly elevated the resistance of Akttg fibroblasts to pro-
teotoxic, genotoxic as well as autophagic stresses. In contrast, rpS6P-/- fibroblasts exhibited
a higher sensitivity to these stresses upon constitutive expression of oncogenic Kras. The
latter result provides a possible mechanistic explanation for the ability of rpS6
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phosphorylation deficiency to enhance DNA damage and protect mice from Kras-induced
neoplastic transformation in the exocrine pancreas. We propose that Akt1 and Kras exert
their oncogenic properties through distinct mechanisms, even though both show addiction
to rpS6 phosphorylation.
Introduction
Pancreatic β-cell mass is a prime determinant of glucose homeostasis and is regulated by a
dynamic balance of proliferation, cell size, apoptosis and neogenesis [1], involving both mito-
genic and growth signals. These signals are initiated by activation of growth factor receptor tyro-
sine kinases, which in turn lead to activation of phosphatidylinositol 3-kinase (PI3K). PI3K
converts the lipid phosphatidylinositol-4,5-P2 (PIP2) into phosphatidylinositol-3,4,5-P3 (PIP3),
in a reaction that can be reversed by the PIP3 phosphatase PTEN (phosphatase and tensin homo-
log deleted from chromosome 10) [2]. PIP3 recruits both 3-phosphoinositide-dependent kinase
1 (PDK1) and Akt to the plasma membrane [3], and PDK1 phosphorylates and activates Akt [4].
There are three closely related isoforms of Akt in mammalian cells, Akt1, Akt2 and Akt3
[5]. Mice, whose β-cells overexpress a constitutively active Akt1 (Akttg) bearing a myristoyla-
tion signal (myr-Akt), display a prominent increase in both the number and size of these cells,
concomitantly with improved glucose tolerance [6, 7]. Likewise, conditional activation of Akt
in β-cells results in fasting hypoglycemia, hyperinsulinemia and improved glucose tolerance
[8]. Akt exerts these effects by phosphorylating tuberous sclerosis complex 2 (TSC2) and
thereby inhibiting the ability of TSC1-TSC2 complex to act as a GTPase-activating protein
(GAP) for Rheb (Ras-homolog enriched in brain). Consequently, the mammalian target of
rapamycin (mTOR) complex 1 (mTORC1) is derepressed. Indeed, mice with conditional dele-
tion of Tsc2 in β-cells exhibit lower glucose levels, hyperinsulinemia and improved glucose tol-
erance. These changes are explained by increases in β-cell mass, proliferation and cell size [9].
The role of mTORC1 as a transducer of some Akt signals is demonstrated by the ability of
rapamycin, an mTORC1 inhibitor, to abolish the Akt1-induced β-cell proliferation [10].
Once mTORC1 is activated it regulates protein synthesis by direct phosphorylation of (a)
eukaryotic initiation factor (eIF) 4E-binding proteins (4E-BP1, 2 and 3), which consequently
dissociate from and derepress eIF4E; and (b) ribosomal protein S6 kinases (S6K1 and 2) which
become fully active and affect the protein synthesis machinery (reviewed in [11]). Consistently,
mice deficient of S6K1 display glucose intolerance, hypoinsulinemia and reduced β-cell size
[12], whereas mice over expressing a constitutively active form of S6K in β-cells display
increased insulin secretion in the absence of changes in β-cell mass [13].
Ribosomal protein S6 is the best-characterized substrate of S6K [14]. A knockin mouse
(rpS6P-/-), in which all five phosphorylatable serine residues of rpS6 were substituted by ala-
nines, displays a small size phenotype that reflects a cell type-specific growth defect in both
pancreatic β-cells and myotubes [15, 16]. Moreover, rpS6P-/- mice have diminished levels of
pancreatic insulin, hypoinsulinemia, impaired glucose tolerance, reduced muscle energy con-
tent, compromised compensatory renal hypertrophy and impaired parathyroid hormone
secretion after experimental uremia [15–18]. Interestingly, we have recently shown that rpS6
phosphorylation deficiency enhances Kras-induced DNA damage in the exocrine pancreas and
consequently boosts p53-mediated tumor suppression [19].
Activation of Akt1 has been detected in approximately half of pancreatic ductal adenocarci-
noma cancer patients [20], and it appears to exert its oncogenic activity in this cancer by over-
coming cell cycle arrest, [21, 22] blocking apoptosis [23, 24], and promoting angiogenesis [25].
The involvement of Akt in carcinogenesis is not confined to the exocrine pancreas, as mice
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expressing constitutively myr-Akt1 in their β-cells exhibit islet hyperplasia leading to insuli-
noma formation. This transformation event is mediated by S6K1 and is fully blocked in S6K1
deficient mice [26].
The parallel roles previously assigned for Akt and its downstream effector, rpS6 phosphory-
lation, as determinants of the size and function of β-cells, as well as of pancreatic tumorigenic-
ity, prompted us to examine whether Akt exerts all these effects by signaling to rpS6
phosphorylation. Surprisingly, we found that Akt1 controls β-cell size in an rpS6 phosphoryla-
tion-independent fashion, yet the development of insulinomas in Akttg mice is abolished if
their β-cells lack rpS6 phosphorylation. Mechanistically, rpS6 phosphorylation deficiency
failed to protect β-cells from Akttg induced aneuploidy, and therefore, does not block insulino-
mas development by interfering with their ploidy. Contrarily, immortalized rpS6P-/- MEFs
exhibit impaired translation fidelity, even in the presence of Akttg, potentially contributing to
the antitumorigenic effect of rpS6 phosphorylation deficiency.
Material and Methods
Animals
Generation of rpS6P-/- knockin as well as RIP-MyrAkt1–expressing mice (Akt1tg) has been pre-
viously described [7, 15]. Both rpS6P-/- and RIP-MyrAkt1 were on C57BL/6 genetic back-
ground. The C57BL/6 rpS6P-/- mice were generated by backcrosses of rpS6P-/- 129/svj with
C57BL/6 Akttg. The rpS6P-/- and Akttg strains were crossed to obtain rpS6P-/+ and Akttg+/- mice,
which were intercrossed to yield Akttg and rpS6P-/-;Akttg, respectively. Mice were genotyped by
PCR analysis using specific primers for myr-Akt: (5’ CAGGCAAGTGTTTGGAAACTGC 3’
and 5’ AAAGGTCTTCATGGTGGCACCGTC 3’) as well as for the rpS6P-/- and rpS6P+/+
alleles [15]. Mouse embryo fibroblasts MEFs were prepared from embryos of S6loxP/loxP;
CreER+ mice at day 13.5 of gestation as described previously [27]. Immortalized MEFs were
obtained by transfection with a plasmid expressing the Simian Virus 40 large T-antigen. Mice
were housed in plastic cages and maintained at 22°C with a 12-hour dark/12-hour light cycle
and had free access to food and water. Notably, all experiments described in Figs 1 and 2 were
carried out with female mice, since the establishment of the role of rpS6 phosphorylation as a
determinant of glucose homeostasis had been originally conducted with female mice [15].
Ethics Statement
The joint ethics committee (IACUC) of the Hebrew University and Hadassah Medical Center
approved the study protocol for animal welfare. The Hebrew University is an AAALAC inter-
national accredited institute. Mice were euthanized by cervical dislocation after anesthesia with
isoflurane. Animals were monitored weekly for body weight, blood glucose and general appear-
ance. Mice that showed severe hypoglycemia (<50 mg/dL glucose) or lost>10% body weight
were euthanized.
Immunofluorescence Microscopy of Pancreas Sections
Five-micron thick sections from formalin-fixed, paraffin-embedded pancreases were prepared.
Slides were rehydrated, blocked with CAS-block (Invitrogen) and incubated overnight at 4°C
with primary antibodies. After washing in PBST slides were incubated for 1 h with fluorescent
secondary antibodies, washed again, incubated briefly with Sytox Green Nucleic Acid Stain
(Invitrogen) and mounted. Digital images of islets and acinar tissue were obtained using an
Olympus BX51 microscope (200 X magnification), based on staining for insulin. The number
of nuclei in a constant area (2500 μm2) was counted manually using Image-Pro Plus software
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Fig 1. Akt overexpression overrides the inhibitory effect of rpS6 knockin on β-cell size and function. (A) Representative images of β-cells of all four
genotypes. Pancreatic sections for WT, rpS6P-/-, Akttg and Akttg; rpS6P-/- 2-month-old mice were immunostained for phospho-rpS6 (green), for Pdx1 (red) and
for DNA by Sytox (blue). All images are set to the same scale. (B) Pancreatic sections from 2-month-old mice were stained for DNA by Sytox and for β-cells
cytoplasm by anti-insulin antibodies. The size of β-cells was derived from the reciprocal value of their density, which represents the number of nuclei in
multiple 2,500-μm2 squares that contained only insulin-positive cells. The relative cell size was attained by normalizing to that of wild type mice, arbitrarily set
at 1. Values are presented as a mean ± SEM of counts derived from 121 to 189 squares within 21 to 31 islets identified in 3 to 6 mice of each genotype. (C) β-
cells were isolated from 2-month-old mice (three wild-type (WT), two Akttg and three rpS6P-/-;Akttg mice), fixed, permeabilized, immunostained for insulin, HA,
Ki67 and Hoechst before FACS analysis. The cell size of quiescent β-cells (HA- and insulin-positive, Ki67-negative) was measured as described in Material
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and Methods. Notably, The percentage of HA-positives in isolated β-cells from 3 rpS6P-/-;Akttg mice was 78.3 ± 0.7 (n = 3) and from 2 Akttg mice was 66.5
(65% and 68%) (D) Pancreatic sections, from 2-mo-old mice of the indicated genotypes, were stained for DNA by Sytox green, for proliferation by anti-Ki67
and for β-cells cytoplasm by anti-insulin antibodies (see S2 Fig for representative islets of all 4 genotypes). The proliferation is presented as % Ki67 positive
within insulin positive cells. Values are presented as a mean ± SEM of counts derived from 20 to 50 islets identified in 3 to 4 mice of each genotype. (E)
Glucose tolerance test. Blood glucose concentrations before and after intraperitoneal injection of 2.5 g D-glucose per kg body weight in 6 to 10-weeks-old
mice fasted for 17 h. The data represent an average ± SEM for at least 11 mice for each genotype. (*) p < 0.002 versus rpS6P-/- mice. (F) Glucose-stimulated
insulin secretion. Serum insulin concentrations before and after intraperitoneal injection of 2.5 g D-glucose per kg body weight in 6 to 10-weeks-old mice,
which had been fasted for 17 h. The data represent an average ± SEM for at least 4 to 7 mice for each genotype. (*) p < 0.05; (**) p < 0.01. (G) The β-cell
area is presented as a mean ± SEM of the percent of total pancreatic area in 3 mice of each of the indicated genotypes.
doi:10.1371/journal.pone.0149995.g001
Fig 2. Rescue of rpS6 phosphorylation deficient mice frommyr-Akt1-induced insulinoma is associated with decreased cell proliferation and
increased p27 nuclear localization. (A) Pancreatic sections of islets from 12-month-oldWT and Akttg mice were stained for phosphorylated rpS6 and
(green) and for β-cells nuclei by PDX1 antibodies (red). (B) Pancreatic sections fromWT, rpS6P-/-, Akttg and rpS6P-/-;Akttg 12-month-old mice were stained by
haematoxylin-eosin. All images presented at the samemagnification (see size bar [100 μm] in WT). Arrows point to islets and the black line (lower left panel)
marks the right margin of the insulinoma. (C) The number of mice with readily detectable insulinoma (dashed-line box) is presented within the total number of
examined Akttg and rpS6P-/-;Akttg mice (open box). (D) Pancreatic sections from1, 2 and 10 to 15-mo-old mice of the indicated genotypes were stained as
described in the legend to Fig 1D (see S3 Fig for representative islets from all 4 genotypes). The proliferation is presented as % Ki67 positive within insulin-
positive cells. Values are presented as a mean ± SEM of counts derived from 20 to 50 islets identified in 3 to 4 mice of each genotype at each time point. (E)
Pancreatic sections from 10 to 15-mo-old mice were stained for p27 and for insulin (see S4 Fig for representative islets from all 4 genotypes). Values are
presented as a mean ± SEM of counts derived from 12 to 42 islets identified in 2 to 4 mice of each genotype. (F) The size of β-cells in 10 to 15-mo-old mice
was analyzed and calculated as described in the legend to Fig 1C. Values are presented as a mean ± SEM of counts derived from 215 to 1252 squares
(2,500- μm2) within 21 to 31 islets identified in 2 to 7 mice of each genotype.
doi:10.1371/journal.pone.0149995.g002
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(Media Cybernetics). The primary antibodies used were guinea pig anti-insulin (Dako), mouse
anti-p27 (Santa Cruz), goat anti-PDX1 (a gift from Christopher VFWright), rabbit anti-phos-
pho rpS6(240/244) (Cell Signaling Technology, Beverly, MA, USA), and rabbit anti-Ki67
(Thermo Scientific). The secondary antibodies used were CY2-anti-guinea pig and CY3-anti
rabbit (Jackson ImmunoResearch). Immunohistochemical staining of pancreatic sections for
HA were carried out with mouse anti-HA (Cell Signaling Technology).
Assessment of β-Cell Area
To assess β-cell area, consecutive paraffin sections, 75 μm apart, spanning the entire pancreas
(approximately 9 sections/pancreas) were stained for insulin and hematoxylin. Digital images
of the entire area of each section at a magnification of x4 were obtained and stitched using
NIS-Elements software, and the fraction of tissue area covered by insulin staining was deter-
mined. The percentage β-cell area was defined as the β-cell area divided by pancreatic section
area, multiplied by 100.
Identification of Insulinomas
Blood glucose was monitored in aged Akttg mice (10 mo. and older) exhibiting distress signs.
Mice with apparent hypoglycemia were sacrificed and their pancreata were subjected to gross
pathological examination. Pancreatic masses at least 2 mm in size in hypoglycemic mice were
defined as insulinomas.
Glucose Tolerance Tests
A glucose tolerance test was performed on fasted (17 h) mice by injecting D-glucose intraperi-
toneally at a dose of 2.5 g/kg body weight. Whole venous blood was obtained from the tail at
the indicated time points after the glucose load. Blood glucose levels were measured using a
glucometer (Bayer).
In vivo Insulin Secretion Tests
Fasted (17 h) mice were intraperitoneally injected with D-glucose at a dose of 2.5 g/kg body
weight. Whole venous blood was obtained from the tail at the indicated time points after glu-
cose load and serum insulin was measured by Ultrasensitive Insulin Mouse Elisa Kit
(CrystalChem).
Cells
Primary and immortalized (SV40 T-antigen transfected) rpS6P+/+ (WT) and rpS6P-/- mouse
embryonic fibroblasts (MEF) were prepared and maintained in culture as previously described
[15]. HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing
10% fetal calf serum, 2 mM glutamine, 100 u/ml penicillin and 0.1 mg/ml streptomycin.
Analysis of β-cell ploidy
Pancreatic islets were isolated and dissociated with trypsin prior to fixation and permeabilization
with Fix/Perm and Perm/Wash solutions (BD Biosciences). Islet cells were then immunostained
for insulin (Guinea Pig anti-insulin [Dako]) or HA (Mouse anti-HA-Tag [Cell Signaling Tech-
nology]) to mark β-cells fromWT or Akttg mice, respectively, and for Ki67 to detect proliferating
cells. Cells were incubated with 10 μg/ml Hoechst 33342 for 10 min. at room temperature. DNA
content of quiescent (G0) β-cells (Ki67-negative) was profiled by flow cytometric analysis of
5,000 to 10,000, using FACSAria cytometer (BD Bioscences) equipped with a UV laser.
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Determination of Size of Isolated Islets Cells
The average cell size in 5,000–10,000-cell samples was assessed using the FACStarplus flow
cytometer (Becton Dickinson) with Cell Quest software. The resulting parameter, mean for-
ward scatter height (FSC-H), is a measure of relative cell size.
Western Blot Analysis
Immunoblotting was performed as described [28], using antibodies against rpS6 (#2217), phos-
pho rpS6(Ser240/244) [#2215], Akt [#9272], phospho Akt(ser473) [#4058], β-actin [#4967], α-
tubulin [#2144], cleaved caspase 3 (Asp175) [#9661], LC3B [#2775], Ras [#3339] from Cell Sig-
naling Technology, Beverly, MA, USA; and against puromycin (clone 12D10) fromMillipore.
All antibodies were diluted 1:1000.
Cloning
Lentiviral vector expressing myristoylated, filled in 1224 bp SalI-ClaI fragment containing con-
stitutively active form of Akt (Myr-Akt [Δ4–129]-HA) was excised from pLNCX1 myr-Akt
and ligated in between filled in NotI and BamHI sites of pHAGE (a lentivirus core plasmid [29]
yielding HAGE2-myr-Akt. Cloning of mouse rpS6 coding sequence with different residues
replacing the phosphorylatable serine residues into pHAGE was carried out in multiple steps:
a) generation of PCR fragments encoding rpS6 with 5 Serine [5S], 5 Alanine [5A], or 5 Aspartic
acid [5D; b) cloning of these fragment into pcDNA3.1; c) a 800 bp PCR fragments generated
using each of the pcDNA3.1 cloned rpS6 variants was digested with BglII and AgeI and ligated
in between BglII and AgeI sites in pEGFP-N1 (Clontech) to yield GFP open reading frame
(ORF) followed in frame by the carboxy terminus of the rpS6 variant. A 1500 bp filled in BglII-
NotI fragment from each of these subclones was ligated in between filled in NotI and BamHI
sites in pHAGE to yield pS65S-GFP, pS65A-GFP and pS65D-GFP.
Virus Production and Infection
Generation of lentiviral vectors was accomplished by a five-plasmid transfection procedure
[30]. Briefly, 293T cells were transfected using polyethylenimine (PEI) procedure with a
pHAGE-derived backbone construct together with four expression vectors encoding the pack-
aging Gag-Pol, Rev, Tat, and the G protein of the vesicular stomatitis virus (VSV-G) (10, 0.5,
0.5, 0.5, and 1 μg, respectively, per 100 mm plate) and 0.5 μg PEI. The mixture was added to
the cells, maintained in the growth medium. In the next morning the medium was replaced
with 5% FBS-containing medium for 4 h and then with 1% FBS-containing medium till the
next morning. Medium was collected 48 h post transfection, spun down at 1500 rpm for 5 min,
and the supernatant was passed through a 0.45- μm filter and kept at 4°C. 5 ml of the viral sus-
pension were treated with 60 μg of polybrene (Sigma) at room temperature for 20 min. and
then added to HEK293 cells in 100 mm plate. 4 h later the 1st viral suspension was removed
and a second 5-ml aliquot of viral suspension was similarly treated and added to the plate till
the next day. 48 h post infection cells were subjected to selection with 3 μg/ml puromycin. Gen-
eration of retroviruses and infection of MEFs was carried out as previously described [31].
Cell Proliferation and Viability
Proliferation was monitored by measuring the A650 of the methylene-blue dye extracted from
stained cells [32]. For viability assessment, cells were harvested and the proportion of viable
cells was monitored by the trypan blue exclusion procedure using the TC10 automated cell
counter (Bio Rad) and following the manufacturer’s instructions.
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Measurement of the Rate of Protein Synthesis
Cells were incubated for 1 h with 1 μM puromycin, and the extent of puromycin incorporated
into the pulse labeled nascent peptides was assessed by Western blot analysis with anti-puro-
mycin antibody.
Polysomal Fractionation
Polysomal fractionation was carried out as previously described [31]. After centrifugation, the
A260 was continuously monitored and recorded by VISIONlite (Thermo Spectronic) attached
to a Genesis 10uv (Thermo Spectronic) spectrophotometer. The gradients were divided into 12
fractions and each was treated at room temperature for 15 min with 0.02% Na+-deoxycholate.
Proteins were precipitated with 10% trichloroacetic acid (60 min at room temp.) and spun
down at 14 krpm of 10 min at 4°C. Ice cold acetone was added to the protein precipitate, mixed
by Vortex mixer and left on ice for 20 min. After spinning down at 14 krpm of 10 min at 4°C
the pellet was dried down, and dissolved for Western blot analysis.
In Gel Proteolysis and Mass Spectrometry Analysis
The proteins in the gel were reduced with 2.8 mMDTT (60°C for 30 min), modified with 8.8
mM iodoacetamide in 100 mM ammonium bicarbonate (in the dark, at room temperature, for
30 min) and digested in 10% acetonitrile and 10 mM ammonium bicarbonate with modified
trypsin (Promega, 1:10) overnight at 37°C. The resulting tryptic peptides were resolved by
reverse-phase chromatography on 0.075 X 200-mm fused silica capillaries (J&W) packed with
Reprosil reversed phase material (Dr. Maisch GmbH, Germany). The peptides were eluted
with linear 65 minutes gradients of 5% to 45% and 15 minutes at 95% acetonitrile with 0.1%
formic acid in water at flow rates of 0.25 μl/min. Mass spectrometry was performed by an ion-
trap mass spectrometer (OrbitrapXP, Thermo) in a positive mode using repetitively full MS
scan followed by collision induces dissociation (CID), with multistage activation, of the 7 most
dominant ion selected from the first MS scan. The mass spectrometry data was analyzed using
the Protein Discoverer 1.3 (ThermoFisher inc.) using both Sequest and Mascot search engines,
searching against the Human section of the Uniprot database. Identifications were filtered
according to mass accuracy and 1% false discovery rate (FDR).
Luciferase Assay
Immortalized MEFs were cotransfected with plasmids expressing Renilla or firefly luciferase
using the Jetprime reagent according to the manufacturer’s (Polyplus-transfection SA, France)
instruction. Harvesting the cells, preparation of the extract and measurement of the luciferase
activities were performed as previously described [33].
Results
Akt1 Overexpression is Dominant Over rpS6 Phosphorylation
Deficiency in Triggering β-Cell Hypertrophy and Enhanced Function
rpS6 phosphorylation deficient mice exhibit decreased β-cell size and impaired glucose tolerance
[15]. The location of Akt1 upstream of rpS6 raised the possibility that Akt1 might induce β-cells
growth, at least partly, by activation of rpS6 phosphorylation. To examine whether rpS6 and
myr-Akt1 alleles interact epistatically, we crossed rpS6P-/- knockin mice [15] with mice overex-
pressing myr-Akt1 in β-cells (Akttg) [7], yielding all four possible genotypes (Fig 1A). Clearly,
constitutive expression of the Akttg resulted in upregulation of the mTORC1 activity, as can be
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judged from the hyperphosphorylation of its downstream target, rpS6, and the dramatic increase
in β-cell size, relative to that of WT cells in both 2-mo- and 12-mo-old mice (Fig 1A and S1 Fig).
Morphometric analysis confirmed the opposite effects of rpS6 phosphorylation deficiency
and constitutive Akt1 activity on β-cell size (smaller β-cells in rpS6P-/- mice and larger β-cells
in Akttg mice, Fig 1A and 1B, as well as [6, 7, 15]). Yet, despite the fact that Akt1 resides
upstream of rpS6 phosphorylation, the lack of rpS6 phosphorylation surprisingly failed to
restrict β-cell size in the double mutant (compare Akttg with rpS6P-/-;Akttg in Fig 1A, 1B and
1C and in S3 and S4 Figs). It has previously been reported that the small-cell-size phenotype of
rpS6P-/- MEFs is accompanied by accelerated proliferation rate, relative to WTMEFs [15].
Likewise, the engagement of rpS6P-/- β-cells in the cell cycle, as exemplified by the percentage
of Ki67-positive cells, significantly exceeds that of their WT counterparts. Interestingly, β-cell
replication was further increased in rpS6P-/-;Akttg mice (Fig 1D).
The reciprocal impact of rpS6 phosphorylation deficiency and constitutively active myr-
Akt1 on β-cell size is reflected in opposite effects on glucose tolerance (Fig 1E) and glucose-
stimulated insulin secretion (Fig 1F), namely impaired in rpS6P-/- while improved in Akttg,
relative to WT. In accordance with the dominance of constitutively active myr-Akt1 over rpS6
phosphorylation deficiency on β-cell size, the deficiency of rpS6 phosphorylation failed to cor-
rect glucose tolerance or insulin secretion in Akttg mice. In fact, rpS6 deficiency further exag-
gerated, rather than inhibited, insulin secretion in Akttg mice (Fig 1F). Interestingly, the
relative total β-cell area in rpS6P-/-;Akttg mice was indistinguishable from that of Akttg mice.
Moreover, these genotypes displayed a 2.4- and 3.1-fold increase, relative to that of rpS6P-/- and
WTmice, respectively (Fig 1G). Conceivably, the apparent similar β-cell area in WT and
rpS6P-/- mice (Fig 1G and [15]), despite the small-cell-size phenotype of rpS6P-/- β-cells, reflects
an elevation in the number of the latters, due to their enhanced proliferation rate (Fig 1D). Col-
lectively, these results indicate that constitutively active myr-Akt triggers increased β-cell mass
and enhances insulin secretion in an rpS6 phosphorylation-independent fashion.
Phosphorylation of rpS6 is Required for the Development of
Akt1-Induced Insulinoma
Akttg mice, but not wild type or rpS6P-/- mice, died at 10–15 months of age as previously
reported [26], and this was preceded by hypoglycemia (data not shown). Pathological analysis
of the dying mice disclosed the development of insulinoma in two thirds of these mice (Fig
2C), twice as many as previously reported for this genotype [26]. Strikingly, while rpS6 phos-
phorylation was nearly excluded from islets of 12-Mo old WT mice, it became readily detect-
able in insulinoma cells in aged-matched Akttg mice (Fig 2A). In order to examine whether
augmented phosphorylation of rpS6 is a byproduct or, alternatively, a prerequisite for the
tumorigenic process, we searched for insulinoma in rpS6P-/-;Akttg mice. Strikingly, none of 12
examined mice exhibited insulinoma, even at the age of 15 months (Fig 2B and 2C).
Monitoring Ki67 positive β-cells disclosed an enhanced proliferation rate of β-cells missing
rpS6 phosphorylation, relative to WT cells at different time points between 1 and 12.5 months
of age (Fig 2D). This observation accords with our earlier report on enhanced proliferation of
rpS6P-/- MEFs [15]. The extent of enhanced proliferation of Akttg β-cells in 1 or 2-Mo old mice
is comparable with that previously documented for 5-weeks old mice of the same genotype [6].
However, while the proliferation of Akttg β-cells is dramatically increased in insulinoma at the
age of 12 month, it is maintained nearly unchanged in rpS6P-/-;Akttg mice at the same age (Fig
2D and S3 Fig). It has previously been reported that the expression of p27Kip, a cyclin-depen-
dent kinase inhibitor [34], is reduced in insulinomas [35]. Consistently with this report, fewer
Akttg β-cells had nuclear p27. Strikingly, rpS6 phosphorylation deficiency rescued nuclear
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localization of p27 in rpS6P-/-;Akttg relative to Akttg β-cells cells (Fig 2E and S4 Fig). These find-
ings suggest an Akt-rpS6-p27 axis that controls β-cell proliferation and insulinomas formation.
Alternatively, however, p27 status might be a just a reflection and not a cause of hyperprolifera-
tion and malignant transformation in Akttg mice.
One explanation for the neutralizing effect of the mutations in rpS6 in aging mice might be
phenotypic changes that lead to a general loss of the dominance of myr-Akt over rpS6 phosphor-
ylation deficiency. However, comparing the β-cell size at different ages disproved this hypothesis,
since the dominance of Akttg over rpS6 phosphorylation deficiency on the cell size phenotype
was preserved in aging mice (Figs 2F, 1B and 1C and S3 Fig [see staining for insulin]).
Collectively, these results imply that the tumorigenic effect of myr-Akt in β-cells is mediated
by rpS6 phosphorylation and is accompanied by augmented cell proliferation at the onset of
the tumor progression, with p27 as a potential effector downstream of Akt and rpS6.
Akt-Induced Aneuploidization of β-Cells is rpS6 Phosphorylation-
Independent
Developmentally programmed polyploidization occurs in multiple mammalian cell types
(reviewed in [36]), including hepatocytes, which become polyploid following a failure of cytoki-
nesis [37]. Interestingly, this inherent hepatic behavior relies on Akt, as pharmacological inhibi-
tion of Akt reduced the frequency of cytokinesis failure events in rat liver. Moreover, oncogenic
Akt was shown to promote genome instability by repressing homologous recombination repair
under pathologic circumstances [38]. It has been proposed that oncogenes induce DNA replica-
tion stress, and thereby genomic instability, which often leads to aneuploidy and eventually to
neoplastic transformation [39]. Based on these observations, we hypothesized that constitutive
expression of Akt might lead to polyploidy or aneuploidy in β-cells, potentially comprising a
mechanism leading to insulinoma.We, therefore, monitored DNA content in β-cells of Akttg
and rpS6P-/- mice and examined how ploidy is affected by rpS6 phosphorylation deficiency. As
shown in Fig 3A, dissociated islet cells from rpS6P-/- and wild type mice displayed similar
amounts of DNA, as assessed by FACS after Heochst staining. In contrast, β-cells from HA+-
Akttg mice were tetraploid on average, but displayed a wide distribution in the intensity of
Hoechst staining (Fig 3B), suggesting excess or lacking chromosomes in many cells. As an inter-
nal control, we took advantage of the mosaic expression of the HA-myr-Akt transgene in β-cells
(expressed in most β-cells, as explained in the legend to Fig 1C and demonstrated in S5 Fig). We
immunostained Akttg cells for the HA tag attached to the transgene and combined it with
Hoechst staining for DNA content. HA+ but not HA- islet cells had a higher DNA content (Fig
3B), demonstrating that constitutively active Akt drives β-cell aneuploidy cell-autonomously.
Thus, β-cell aneuploidy is triggered by constitutive activity of Akt. This novel effect of Akt could
theoretically contribute to the oncogenic effect of Akt in β-cells and other systems.
We then tested how rpS6 phosphorylation impacts β-cell ploidy. Strikingly, islet cells of
rpS6P-/-;Akttg mice were aneuploid to a similar extent as cells from Akttg mice (Fig 3C). Thus,
rpS6 phosphorylation is not required for Akt-induced aneuploidy. Combined with the inhibi-
tory effects of rpS6 mutants on insulinoma development, this finding indicates that aneuploidy
is not sufficient for malignant transformation of β-cells, and that deficient phosphorylation of
rpS6 does not prevent insulinomas development by interfering with ploidy.
Immortalized MEFs as an Experimental Model to Study the
Antitumorigenic Effect of rpS6 Phosphorylation Deficiency
The protection against the development of Akt-induced insulinoma in rpS6P-/-;Akttg mice
could not be explained by either restrained proliferation rate or altered ploidy of β-cells. Hence,
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Fig 3. Constitutive expression of Akt induces polyploidy regardless of the rpS6 phosphorylation
status. A. rpS6 deficiency does not affect ploidy in β-cells. Islets were isolated from wild-type (WT) and 2
month-old Akttg mice. Dissociated islets were fixed, permeabilized, immunostained for Insulin, HA, Ki67 and
Hoechst before FACS analysis. The DNA content of 5,000 to 10,000 quiescent β-cells (insulin-positive,
Ki67-negative) was measured by FACS analysis. B. 5,000 quiescent (Ki67-negative) β-cells (insulin-positive)
that express myr-Akt (HA-positive) are polyploidy, whereas their HA-negative counterpart shows mostly a
diploid profile as wild-type β-cells. C. rpS6 deficiency does not affect the ploidy profile of myr-Akt expressing
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we established an experimental model, based on immortalized WT and rpS6P-/- MEFs [15] for
exploring the underling mechanism.
We have previously shown that the development of precursor lesions for pancreatic ductal
adenocarcinoma (PanIN lesions), in response to either chemical carcinogenesis or expression
of transgenic mutant Kras, is greatly attenuated in rpS6P-/- mice. Furthermore, acinar to ductal
metaplasia regions in rpS6P-/- mice displayed elevated DNA damage markers, specifically
responding to double strand breaks [19]. Hence, protection from cancer in rpS6P-/- mice was
likely due to enhanced elimination of damaged cells. Hence, we initially examined the validity
of our in vitro experimental system, by relying on Kras.
WT and rpS6P-/- MEFs were infected with a retrovirus expressing Kras, bearing the same
mutation as in the mouse pancreas (RasG12D). The resulting cells had increased Ras expression
relative to uninfected cells (Fig 4A), and had higher level of Ser473 phosphorylation in Akt, as
has previously been shown [40]. Fig 4B demonstrates an enhanced rate of proliferation, as
inferred from the population doubling time (td), in Ras
G12D expressing MEFs (13.4 h), relative
to that of WTMEFs (td = 25.4 h, Fig 5B).
To induce a genotoxic stress, MEFs were treated with etoposide, which prevents re-ligation
of the DNA strands, through inhibition of topoisomerase II enzymes, leading to DNA breaks
and consequently leads to apoptosis [41, 42]. Interestingly, when rpS6P-/-;RasG12D MEFs were
subjected to such a treatment they exhibited enhanced sensitivity, relative to RasG12D MEFs, as
β-cells. Islets were isolated from 2 month-old mice (three wild-type (WT), two Akttg and three rpS6P-/-;Akttg
mice) and 5,000 to 10,000 HA-positive β-cells processed as in (A) for FACS analysis.
doi:10.1371/journal.pone.0149995.g003
Fig 4. rpS6 phosphorylation deficiency renders RasG12D MEFsmore sensitive to both genotoxic and proteotoxic stresses. (A) Immortalized WT,
rpS6P-/-, RasG12D and rpS6P-/-;RasG12D MEFs were harvested and their cytoplasmic proteins were subjected to Western blot analysis with the indicated
antibodies. (B) RasG12D and rpS6P-/-;RasG12D MEFs were seeded in 96-well plates at a density of 4 x103 per well. Proliferation was monitored by measuring
the A650 of the methylene-blue dye extracted from stained cells [32]. Absorbance measured 24 h after platting, was set arbitrarily at 1 and absorbance
measured at later time points (average ± SEM [n = 6]) for each time point) was normalized to that value. td, population-doubling time. (C) Immortalized
RasG12D and rpS6P-/-;RasG12D MEFs were incubated with the indicated concentrations of etoposide for 24 h, harvested and their cytoplasmic proteins were
subjected to Western blot analysis with the indicated antibodies. (D) Immortalized RasG12D and rpS6P-/-;RasG12D MEFs were incubated with the indicated
concentrations of MG132 for 24 h, harvested and their cytoplasmic proteins were subjected to Western blot analysis with the indicated antibodies.
doi:10.1371/journal.pone.0149995.g004
RpS6 Phosphorylation Is a Determinant of Insulinoma Development
PLOS ONE | DOI:10.1371/journal.pone.0149995 February 26, 2016 12 / 25
Fig 5. rpS6 phosphorylation deficiency increases proliferation and decreases translational fidelity in fibroblasts. (A) Immortalized WT, rpS6P-/-, Akttg
and rpS6P-/-;Akttg MEFs were harvested and their cytoplasmic proteins were subjected to Western blot analysis with the indicated antibodies. (B) MEFs
described in (A) were seeded in 96-well plates at a density of 4 x103 per well. The proliferation of MEFs described in (A) was monitored as described in (Fig
4B). td, population doubling time. (C) WT and rpS6
P-/- immortalized MEFs were incubated for 1 h with 1 mM puromycin, harvested and their cytoplasmic
proteins were subjected to Western blot analysis with the indicated antibodies. (D) Quantification of signals obtained in 6 experiments similar to that
described in (C). (E) WT, rpS6P-/-, Akttg, and rpS6P-/-;Akttg MEFs were cotransfected with Renilla luciferase expression vector and any one of the following
firefly luciferase expression vectors: Fluc(WT), Fluc(Stop) and Fluc(R218S). The transfection efficiency of any of the Fluc constructs was normalized to that
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exemplified by the reduced appearance of cleaved caspase 3 (Fig 4C). These results are in a
good agreement with the increased DNA damage documented in PanIN lesions of rpS6P-/-;
RasG12D vs. RasG12D mice, and support the hypothesis that absence of rpS6 phosphorylation
may negate Kras-driven cancer development by enhancing tumor suppressive DNA damage
[19]. This hypersensitivity is not confined just to genotoxic stress, as rpS6 phosphorylation
deficiency rendered Kras-expressing MEFs more sensitive to a proteasome inhibitor, GM132,
that blocks both normal protein turnover and removal of aberrant proteins (Fig 4D).
The Nuclear Proteins Topoisomerase 2b and Psip1 Selectively Bind
Unphosphorylatable rpS6
rpS6 phosphorylation deficiency exerts a wide range of effects that include reduced cell size,
increased proliferation rate, reduced insulin secretion from beta cells [15], tumor suppression
in pancreata expressing Akttg or RasG12D (Fig 2C and [19]), and altered apoptotic response to
proteotoxic and genotoxic stressors in fibroblasts (Fig 4). To better understand these effects we
searched for proteins that selectively interact with unphosphorylatable rpS6. First, we infected
HEK293 cells with lentiviral vectors expressing three different rpS6-GFP chimeric proteins:
pS65S-GFP (rpS6 with 5 phosphorylatable serine residues, equivalent to WT), pS65A-GFP (S to
A replacement of all phosphorylatable serine residues, equivalent to rpS6P-/- mutant) and
pS65D-GFP (S to D replacement of all phosphorylatable serine residues, phosphomimetic
mutations). The detection of the GFP moiety within polysomal fractions indicated that all
three mutants were not only expressed in the cell, but also assembled into translating ribo-
somes (S6 Fig). Whole cell extracts from these cells were prepared, GFP-tagged proteins were
pulled down and were subjected, together with their interactors, to mass spectrometric analysis.
Table 1 presents six proteins that were identified to specifically bind pS65A-GFP, but not GFP
alone, pS65S-GFP or pS65D-GFP.
Surprisingly, three of the pS65A-GFP-binding proteins, Psip1 (PC4 and SFRS1-interacting
protein 1, also known as LEDGF), TOP2B (topoisomerase IIβ) and SRSF1 (Serine/arginine-
rich splicing factor 4), are nuclear. It has previously been shown that genotoxicity of etoposide
is TOP2B-dependent [43, 44] and that Psip1 is involved in DNA repair, among its other func-
tions [45]. Clearly, even though these interacting partners of unphosphorylated rpS6 might
provide a link between rpS6 and DNA damage response, additional experiments will be
required for establishing such a functional relationship.
rpS6 Phosphorylation Deficiency Accelerates Cell Proliferation and
Decreases Translational Fidelity In Vitro
The consistency of the results obtained for Kras in vitro with those obtained in vivo, prompted
us to use immortalized MEFs to approach the mechanism underlying the antitumorigenic
effect of rpS6 phosphorylation in the presence of constitutively active Akt1. WT and rpSP-/-
MEFs were infected with a lentivirus expressing myr-Akt (Fig 5A). A higher rate of prolifera-
tion was observed in rpS6P-/-, relative to WTMEFs, in a close agreement with that observed in
β-cells of these genotypes (compare Fig 5B with Fig 2D). Moreover, the proliferation of
rpS6P-/-;Akttg MEFs was attenuated relative to Akttg immortalized MEFs (Fig 5B), although the
effect was markedly less than that observed for β-cells from 12-mo-old mice (compare Fig 5B
of the Renilla luciferase. The relative Fluc activity of each mutant was normalized to Fluc (WT). The result obtained for each mutant in WTMEFs (n = 24) was
arbitrarily set at 1 and the relative luciferase activity obtained for each Fluc mutant in rpS6P-/- MEFs (n = 24) was normalized to that value. Similarly, results
obtained for each mutant in Akttg MEFs (n = 12) were arbitrarily set at 1 and the relative luciferase activity obtained for each Fluc mutant in rpS6P-/-;Akttg
MEFs (n = 12) was normalized to that value.
doi:10.1371/journal.pone.0149995.g005
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with Fig 2D). This difference might reflect the fact that both Akttg and rpS6P-/-;Akttg MEFs are
immortalized, whereas in 12-mo-old mice only the Akttg, but not rpS6P-/-;Akttg, β-cells are
transformed.
It has been previously shown that increased rate of protein synthesis leads to decreased
translation fidelity [46]. Since primary rpS6P-/- MEFs have higher rates of both proliferation
and protein synthesis [15], we hypothesized that the fidelity of the translation in this genotype
might be impaired. Hence, we monitored the rate of protein synthesis in immortal WT and
rpS6P-/- MEFs by pulse labeling of nascent peptide chains with puromycin. Although the differ-
ence between the two genotypes was statistically insignificant, rpS6P-/- MEFs displayed a ten-
dency toward a higher rate of protein synthesis, which is consistent with the faster proliferation
(Fig 5C and 5D).
To test if this tendency might correlate with decrease translation fidelity, we transfected
cells with two luciferase reporters: a) Fluc(R218S), in which the arginine at the active-site (posi-
tion 218) was mutated into serine that renders the resultant mutant protein devoid of enzy-
matic activity [46], and b) Fluc(Stop) that has leucine at position 210 replaced with a stop
codon, which leads to the synthesis of a truncated and enzymatically inactive protein product
[46]. Fig 5E shows that rpS6 phosphorylation deficiency significantly reduced translation
Table 1. List of proteins that selectively interact with unphosphorylatable form of rpS6. Whole cell extract from HEK293 cells infected with pS6[5S]-
GFP, pS6[5A]-GFP, pS6[5D]-GFP or pEGFP-N1, was subjected to GFP pull-down, and the bound proteins were size fractionated by SDS-polyacrlamide gel
electrophoresis. Mass spectrometric analysis of proteins in each lane was performed as described in “material and Methods” and proteins, selectively bound
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c No. of unique peptides—Displays the number of peptide sequences unique to a protein group.
doi:10.1371/journal.pone.0149995.t001
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fidelity, as judged by the increased luciferase activity if transfected with Fluc(R218S), and to a
much lesser extent if transfected with Fluc(Stop). The reason for the apparent difference
between the two reporters is presently unclear. Nevertheless, rpS6 phosphorylation deficiency
induced a 2.6-fold reduction in the translation fidelity in rpS6P-/-;Akttg, relative to Akttg MEFs,
regardless of the luciferase mutant used (Fig 5E). These results indicate that while rpS6 phos-
phorylation deficiency increases overall protein synthesis, it compromises translation fidelity.
Reduced fidelity of translation suggests a mechanism for how rpS6 phosphorylation deficiency
may interfere with tumorigenesis.
rpS6 Phosphorylation Deficiency Confers Resistance to Proteotoxic, or
Genotoxic Stresses in Akt1 Expressing MEFs
One consequence of the lower translation fidelity in rpS6P-/- and rpS6P-/-;Akttg MEFs might be
a higher sensitivity to proteotoxic stress, as has previously been shown for cells with excessive
protein synthesis [46]. To examine this possibility, cells were treated with MG132. Unexpect-
edly and in a contrast to data obtained with rpS6P-/-;RasG12D, rpS6 phosphorylation deficiency
diminished MG132-induced apoptosis in both rpS6P-/- and rpS6P-/-;Akttg MEFs (Fig 6A). This
seemingly protective role of rpS6 phosphorylation deficiency is also reflected in the survival of
the different genotypes under this stress, as assessed by trypan blue exclusion (Fig 6B). Notably,
this behavior is not an artifact of the immortalized cells, as primary rpS6P-/- MEFs demon-
strated a similar resistance to MG132, relative to their WT counterparts (Fig 6C).
Next, we examined the sensitivity of rpS6P-/- and rpS6P-/-;Akttg MEFs to genotoxic stress. As
with MG132 treatment, rpS6 phosphorylation deficiency surprisingly rendered wild type as
well as Akttg MEFs more resistant to the etoposide-induced apoptosis (Fig 6D). Thus, fibro-
blasts became more resistant to both genotoxic and proteotoxic stress in the absence of rpS6
phosphorylation, regardless of the expression of active Akt.
Collectively, these data support the notion that the phosphorylation status of rpS6 affects
cellular sensitivity to stress in a context-dependent manner, i.e. rpS6 phosphorylation appears
to render Kras-expressing cells more resistant to stress, while it renders Akt-expressing cells
more sensitive to stress.
rpS6 Phosphorylation Deficiency Exerts no Effect on the Autpohagic
Response of MEFs Expressing Akt1
Autophagy impairs early cancer development, while facilitating advanced tumor progression,
by serving a dual function during tumorigenesis. Thus, on the one hand its homeostatic role
enables lysosomal digestion and recycling of cellular contents, and thereby limits genome-dam-
aging events that would otherwise favor tumor initiation. On the other hand, however, the abil-
ity of autophagy to help cells mitigate stress facilitates advanced tumor progression [47]. To
test whether the phosphorylation status of rpS6 might affect autophagy we treated cells with
rapamycin in the presence or absence of chloroquine. Rapamycin mimics the effect of amino
acid starvation by inhibiting mTORC1 and thereby is expected to induce autophagy [48], even
if its effect is not always readily detectable [49]. Chloroquine inhibits the fusion of autophagy
vacuoles with the lysosome [50] and thereby enables their accumulation and the detection of
their marker, LC3-II [51]. The results of this experiment demonstrate that autophagy not only
was not enhanced in rpS6P-/-;Akttg MEFs relative to Akttg MEFs, it might even have been sup-
pressed (Fig 7).
It should be pointed out, however, that the apparent resistance of rpS6-phophorylation defi-
cient Akttg MEFs to proteotoxic, genotoxic and autophagic stresses does not necessarily reflect
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Fig 6. rpS6 phosphorylation deficiency rendersWT or Akttg MEFsmore resistant to a proteotoxic and genotoxic stress. (A) Immortalized WT,
rpS6P-/-, Akttg, and rpS6P-/-;Akttg MEFs were incubated with the indicated concentrations of MG132 for 16 h, harvested and their cytoplasmic proteins were
subjected to Western blot analysis with the indicated antibodies. (B) Viability of cells described in (A) was assessed by the Trypan blue exclusion assay, as
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the behavior of rpS6P-/-;Akttg β-cells within the pancreas. Evidently, novel experimental sys-
tems need to be designed in order to establish these issues in vivo.
Discussion
Aberrant mTOR signaling in tumors is due to either loss of function of upstream tumor sup-
pressor proteins, like PTEN and TSC, or activating mutations within oncogenes that feed into
the mTOR pathway. Hyperactivation of the PI3K-Akt pathway is a feature of a large majority
of cancer cell types [52]. Indeed, amplification, overexpression, and activation of Akt occur at
high frequency in a number of human cancers [53, 54].
It has previously been shown that rpS6 phosphorylation is critical for Kras-induced PanIN
lesion formation in the exocrine pancreas and for full-blown pancreatic ductal adenocarcinoma
described in Material and Methods. The percentage of viable cells (average of six wells for each time point) is presented as mean ± SEM (the size of the
symbol for most measurements was larger than the respective SEM). (C) Primary WT and rpS6P-/- MEFs (passage 3) were analyzed as described in (A). (D)
Immortalized WT, rpS6P-/-, Akttg, and rpS6P-/-Akttg MEFs were incubated with the indicated concentrations of etoposide for 24 h, harvested and their
cytoplasmic proteins were subjected to Western blot analysis with the indicated antibodies.
doi:10.1371/journal.pone.0149995.g006
Fig 7. The phosphorylation status of rpS6 plays no role in autophagy. (A) Immortalized Akttg and
rpS6P-/-;Akttg, MEFs were either untreated, incubated with 20 nM rapamycin, 50 μM chloroquine or both for 16
h. Cells were harvested and their cytoplasmic proteins were subjected to Western blot analysis with the
indicated antibodies. (B) The signals of LC3-II, obtained in Western blot analyses of two independent
experiments, as described in (A), were quantified and normalized to that tubulin. The fold change in the
expression of LC3-II upon addition of rapamycin, chloroquine or both, was related to that of untreated cells,
which was arbitrarily set at one.
doi:10.1371/journal.pone.0149995.g007
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induced by a carcinogen [19]. The present report expands the reliance on rpS6 phosphoryla-
tion to tumor development in the endocrine pancreas. It should be noted, however, that this
dependence does not reflect a general mechanism, but rather a tissue specific phenomenon.
Thus, AktT mice, in which a constitutively active Akt2 is expressed in immature T cells, develop
spontaneous thymic lymphomas, which cannot be prevented in rpS6P-/-;Akttg MEFs double
mutant mice. It appears, therefore, that rpS6 is dispensable for transformation downstream of
oncogenic Akt signaling in the thymus [55].
Activated Akt modulates the function of numerous substrates, which regulate many cell
processes [56]. Conceivably, the expression of constitutively active Akt1 could induce insuli-
noma via activation of the mTORC1 pathway and thereby its downstream effectors, S6K1 and
rpS6 phosphorylation in β-cell ([26] and the present report). The present study demonstrates a
dominance of constitutively active Akt over rpS6 phosphorylation deficiency in regulating β-
cell size, total β-cell area, glucose homeostasis and ploidy (Figs 1, 2 and 3).
The ability of Akt to increase cell size independently of its downstream effector rpS6 is not
unprecedented. Exercise, pressure overload or forced activation of the PI3K/Akt pathway
induce cardiac hypertrophy that correlates with elevated S6K1 activity and S6 phosphorylation
([57] and references therein). However, deletion of S6K1 and S6K2 and thereby elimination of
rpS6 phosphorylation had no impact on the development of pathological, physiological, or
genetically induced cardiac hypertrophy [57]. These results imply that cardiac hypertrophy,
even when induced in a PI3K/Akt-dependent manner, does not rely on S6K activation or rpS6
phosphorylation, consistently with our findings in β-cells.
One plausible model, which might explain this seemingly paradoxical observation, is that
Akt exerts its stimulatory role on cell size through mutually exclusive pathways: one is rpS6
phosphorylation-dependent and the second is rpS6 phosphorylation-sensitive. Hence, defi-
ciency of S6K activity or rpS6 phosphorylation alleviates repression of the alternative pathway,
and thereby enables Akt-induced increase in cell size in an rpS6 phosphorylation-independent
fashion. Contrarily, data presented here clearly support the notion that Akt appears to fully
rely on rpS6 phosphorylation when operating as an oncogene.
Ribosomopathies are a set of genetic diseases that are collectively characterized by ribosome
hypofunction at the cellular level. Patients initially show hypoproliferative disorders like ane-
mias and bone marrow failure, but tend to develop cancer at a letter stage ([58] and references
therein). We show here that rpS6 knockin mutant β-cells are protected from the development
of Akt-induced insulinoma, in a manner that resembles that observed in early human riboso-
mopathies (i.e. suppressed proliferation). Moreover, we demonstrate here for the first time that
the rpS6 phosphorylation deficiency is associated with about 2.6-fold decrease in translation
fidelity in cells expressing a constitutively active Akt (Fig 5E). It should be noted, however, that
we have not establish a causal relationship between the reduced translation fidelity and the
anti-tumorigenic effect of the mutant rpS6. Likewise, we could not exclude the possibility that
the reduced translation fidelity reflects the five serine to alanine substitutions in rpS6P-/- MEFs,
rather than phosphorylation deficiency of this ribosomal protein.
Many of the phenotypic manifestations of mouse deficient of S6K1 are recapitulated in the
rpS6 knockin mouse. Thus both these mutants exhibit: a) small β-cell size phenotype that is
accompanied by hypoinsulinemia and impaired glucose homeostasis (Fig 1E and 1F and refer-
ences [12, 15]); b) small myoblasts and reduced muscle mass [16, 59]; and c) blunted compen-
satory renal hypertrophy following contralateral nephrectomy [18, 60]. Clearly, based on these
observations it is tempting to argue that this phenotypic similarity reflects the fact that rpS6
phosphorylation is an important S6K1 effector. However, this explanation is inconsistent with
the observation that rpS6 is still fully phosphorylated in S6K1 deficient mouse, due to the com-
pensatory activity of S6K2 [26, 59, 61]. It appears, therefore, that rpS6 phosphorylation
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deficiency restrains the development of insulinoma by a mechanism that is distinct from that
operated in S6K1 knockout mice.
rpS6 phosphorylation has been proposed to reduce Kras-induced DNA damage in acinar
cells and in acinar-to-ductal metaplasia, and consequently attenuates p53-mediated tumor sup-
pression [19]. Here we show that rpS6 phosphorylation deficiency renders RasG12D MEFs con-
siderably more sensitive to both proteotoxic and genotoxic stresses than RasG12D MEFs
expressing a phosphorylatable rpS6 (Fig 4). Moreover, pull-down experiments have demon-
strated a preferential binding of unphosphorylatable (rpS6P5A-GTP) rpS6 chimeric protein to
Psip1, a nuclear component of the DNA repair machinery [45], but not of the phosphorylatable
(rpS6P5S-GTP) or phosphomimetic (rpS6P5D-GTP) proteins. Collectively, these observations
support a model that the oncogenic activity of K-Ras results in increased DNA damage, whose
repair is impeded by rpS6P-/—mediated interference and consequently cells are removed by
apoptosis and thereby the tumorigenic process is blocked.
Surprisingly, rpS6 phosphorylation deficiency renders WT or Akttg MEFs, unlike RasG12D
MEFs, more resistant to both proteotoxic and genotoxic stresses than rpS6P-/- or rpS6P-/-;Akttg
MEFs (Figs 4 and 6). These results suggest that Akt1 and Kras exert their oncogenic properties
through distinct mechanisms, even though both show addiction to rpS6 phosphorylation.
Notably, the expression of both oncogenic Ras and Akt induces DNA damage, consequently
both Ras- and Akt-induced cancer cells mitigate DNA damage to a level that does not impair
their proliferation (reviewed in [62, 63]).
Given that mTORC1 is activated in more than 50% of human cancers [64], there has been
much interest in using rapamycin and its analogs (rapalogs) to treat tumors. However, rapa-
logs have had limited success as single-agent cancer therapies in hundreds of clinical trials to
date [65]. One reason for this resistance is that downregulation of mTORC1, and conse-
quently of S6K1, relieves the feedback inhibition exerted by the latter on IRS-1, and thereby
upregulates the PI3K-Akt signaling [66]. Hence, development of agents to specifically target
rpS6 phosphorylation, rather than S6K activity, in combination with drugs aimed at
upstream targets, might be much more beneficial for treating tumors that display addiction
to this modification.
Finally, this study evokes an intriguing question regarding the mechanism(s) underlying the
role of rpS6 phosphorylation in regulating processes as diverse as cell growth, glucose homeo-
stasis and pro-oncogenic activity, particularly given that rpS6 is primarily a structural protein
of the ribosome. Several explanations can be proposed to account for these unique physiologi-
cal functions of rpS6 phosphorylation: (a) the phosphorylation of rpS6 within, or outside the
ribosome affects the translation efficiency of specific mRNAs, has yet to be identified; (b) rpS6
might be one of the many bifunctional ribosomal proteins, that can carry out extraribosomal
tasks often unrelated to the mechanics of protein synthesis [67]; and (c) phosphorylated rpS6
might not affect protein synthesis, but instead interact with cellular protein(s), which conse-
quently becomes active or inactive, and thus affects the cell physiology. Indeed, rpS6P-/- mice
show altered transcription of the ribosome biogenesis program [68]. Moreover, we show here
that several extraribosomal proteins coimmunoprecipitated with rpS6, suggesting an in vivo
interaction, either directly or indirectly, with these proteins.
Supporting Information
S1 Fig. Representative images of β-cells stained for Phospho-rpS6. Pancreatic sections for
WT, rpS6P-/-, Akttg and Akttg; rpS6P-/- 10 to 15-month old mice were immunostained for phos-
pho-rpS6 (green), Pdx1 (red), DNA (blue). All images are set to the same scale.
(TIF)
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S2 Fig. Representative images of β-cells stained for Ki67. Pancreatic sections for WT,
rpS6P-/-, Akttg and Akttg; rpS6P-/- 2-month old mice were immunostained for insulin (green),
Ki67 (red), and DNA (blue). All images are set to the same scale.
(TIF)
S3 Fig. Representative images of β-cells stained for Ki67. Pancreatic sections for WT,
rpS6P-/-, Akttg and Akttg; rpS6P-/- 10 to 15-month old mice were immunostained for insulin
(green), Ki67 (red), and DNA (blue). All images are set to the same scale.
(TIF)
S4 Fig. Representative images of β-cells stained for p27. Pancreatic sections for WT, rpS6P-/-,
Akttg and Akttg; rpS6P-/- 10 to 15-month old mice were immunostained for insulin (green), p27
(red), and DNA (blue). All images are set to the same scale.
(TIF)
S5 Fig. Representative images of β-cells stained for HA. Pancreatic sections for WT, rpS6P-/-,
Akttg and Akttg; rpS6P-/- 10 to 15-month old mice were immunostained for HA. All images are
set to the same scale. Note, a dashed line marks the boundaries of the islets in images of sec-
tions fromWT and rpS6P-/- pancreata.
(TIF)
S6 Fig. Recombinant rpS6-GFP is assembled into translating ribosomes regardless of its
phosphorylation status.HEK293 cells were infected with lentivirus expressing rpS6(5S)-GFP,
rpS6(5A)-GFP, or rpS6(5D)-GFP fusion proteins or were uninfected (u.i.). Cells were harvested
and their cytoplasmic extracts were size fractionated by centrifugation through sucrose gradi-
ent. The tube content was collected from the bottom, and the absorbance at 260 nm was
recorded (upper panels). The vertical dashed line separates the polysomal fractions (1 to 8)
from the subpolysomal fractions (9 to 12). Proteins from the indicated fractions were subjected
to Western blot analysis with the indicated antibodies (lower panels).
(TIF)
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